DWJ211 / Daewoong Pharma - LARVOL DELTA

Pharmacokinetics and Safety, Tolerability of DWJ211in Healthy Volunteers (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: Daewoong Pharmaceutical Co. LTD. | Unknown status ➔ Completed

Trial completion

Clinicial Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat (clinicaltrials.gov) - P2 | N=140 | Completed | Sponsor: Daewoong Pharmaceutical Co. LTD. | Unknown status ➔ Completed

Trial completion

SMF: Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat (clinicaltrials.gov) - P3 | N=148 | Completed | Sponsor: Daewoong Pharmaceutical Co. LTD. | Unknown status ➔ Completed

Trial completion

A Randomized, Double-Blind, Multi-Center, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of DWJ211 in the Treatment of Moderate to Severe Submental Fat. (PubMed, Dermatol Ther) - "The 1% DWJ211 dose was beneficial for SMF reduction and had a tolerable safety profile. Thus, we selected 1% as the dose to be tested in a Phase 3 clinical trial."

Clinical • Journal • P2 data • Pain

Pharmacokinetics and Safety, Tolerability of DWJ211in Healthy Volunteers (clinicaltrials.gov) - P1; N=18; Not yet recruiting; Sponsor: Daewoong Pharmaceutical Co. LTD.

Clinical • New P1 trial